

Index

A

Acute lymphoblastic leukemia (ALL), 144–146
Acute myeloid leukemia (AML), 2, 136–140,
144–147, 212
Acylprotein thioesterase (APT), 66
Akt, 17, 31, 33, 35, 38, 69
ALL. *See* Acute lymphoblastic leukemia
AMD3100, 164
AML. *See* Acute myeloid leukemia
AMPK, 68
APP, 271
APT. *See* Acylprotein thioesterase
ARAF, 13, 16, 19–20, 95, 243–244
ARE, 97
ArhGAP29, 8
Atg13, 33
ATR, 208

B

B cell, KRAS modulation in cancer, 187–188
BCAAs. *See* Branched-chain amino acids
BCL-XL, 204, 213
BRAF, 13, 16–17, 19–20, 38, 95, 207–208, 243–249, 252
Branched-chain amino acids (BCAAs), 207

C

CAECAM1, 100
CAPRI, 259, 265
Cardio-facio-cutaneous syndrome, 18
CDC25, 2–3, 47
CDC42, 4–5, 8, 71, 89, 97
Cell polarity, MRAS role, 96–97
CHK1, 208
Chronic myelomonocytic leukemia (CMML), 137–140
CMML. *See* Chronic myelomonocytic leukemia
Cobimetinib, 250
CRAF, 13, 16–17, 19–20, 95, 99, 243–246, 249, 252
CXCL1, 181–183
CXCL2, 181–183
CXCL5, 181–183
CXCL8, 181–182

D

Dabrafenib, 248
DCAI, 233
DDAH, 271
DDHC9, 65

E

E-cadherin, 36
ELK1, 94
EMT. *See* Epithelial-to-mesenchymal transition
Epac, history of study, 5–6
Epithelial-to-mesenchymal transition (EMT)
MRAS role, 97
KRAS tumors, 208, 236
ERK. *See* Extracellular regulated kinase
ETEA, 263
EVH1, 271–272
Extracellular regulated kinase (ERK). *See also*
Mitogen-activated protein kinase
domain organization, 251
inhibitors, 127–128, 250, 252
RAF as substrate, 21
Ras
effector, 3
MRAS activation, 95
nanocluster signaling, 87
therapeutic targeting in pancreatic cancer, 127–128

F

FAK. *See* Focal adhesion kinase
Farnesyltransferase, 63–65
FGD5, 8
FIP200, 33
FKBP, 232
Focal adhesion kinase (FAK), 271
14-3-3
Raf
binding, 16–17
displacement, 18–19
Ras signaling mediation, 243

G

Galactin-1, 87
Galactin-3, 87
GAPs. *See* GTPase-activating proteins
GATA2, 206
GCP16, 65
GIT, 97
GLUT1, 207
GM-CSF. *See* Granulocyte–macrophage colony-stimulating
factor
Granulocyte–macrophage colony-stimulating factor
(GM-CSF), 185–186
GRB2, 31

Index

- GTPase-activating proteins (GAPs). *See also specific proteins*
activation, 260–262
activity regulation, 263, 265
classification, 258–260
diseases, 266
dual-target specificity and mechanism variation,
265–266
GAP-related domain, 267–268
G protein–coupled receptor signaling cross talk,
272–273
membrane translocation, 262–263
overview, 257–258
structure, 258, 260–261
- H**
- Hepatocyte growth factor (HGF), 98
HGF. *See* Hepatocyte growth factor
HRAS
G domain structure comparison between isoforms,
107–110
history of study, 1–2
PI3K signaling, 27, 32
plasma membrane interactions, 84
posttranslational modifications, 65–67, 69–70
Hsp90, Raf complex, 17
- I**
- ICMT, 63–64, 212, 223
IDH, 136
IL-6. *See* Interleukin 6
IL-10. *See* Interleukin 10
Inflammation, KRAS modulation in cancer, 191–193
Interleukin 6 (IL-6), 183–184
Interleukin 10 (IL-10), 184
Internal ribosome entry site (IRES), 137
IQGAPs, 259–260
IRA1, 266
IRA2, 266
IRES. *See* Internal ribosome entry site
IRS1, 33
- J**
- JAK/STAT, 205
JMML. *See* Juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML), 136,
138–140
- K**
- Kinesin-1, 271
KR12, 236
KRAS
colon organoids, 176
conformational change on activation, 111
G domain structure comparison between isoforms,
107–110
history of study, 1–2, 4
immune modulation in cancer
B cell, 187–188
CXCL1, 181–183
CXCL2, 181–183
CXCL5, 181–183
CXCL8, 181–182
 $\delta\gamma$ T cell, 188–189
granulocyte–macrophage colony-stimulating
factor, 185–186
inflammation, 191–193
interleukin 6, 183–184
interleukin 10, 184
macrophage, 186–187
nuclear factor κ B, 179–180
overview, 179–181
stellate cell, 189–191
Th17 cell, 188
therapeutic targeting, 194–195
transforming growth factor β , 184–185
inhibitor development
dimer and multimer targeting, 223–224
disulfide tethering, 222
effector interaction targeting, 221
membrane localization targeting, 222–223
nucleotide exchange targeting, 220–221
overview, 219–220
posttranslational modification targeting, 223
prospects, 224
screening in silico, 221–222
lung cancer mouse models
overview, 154–155
pharmacological studies, 157–158
prospects, 164–165
therapeutic models
K-Ras^{FSG12D}, 156–157
K-Ras^{LA2}, 155
K-Ras^{LSLG12D}, 155–156
K-Ras^{LSLG12V^{geo}}, 155–156
Spc-rtTA-tetO-K-RAS4b^{G12D}, 156–157
tumor initiation models, 155
mutation in cancer, 201–202
pancreatic cancer
mouse models
Flp/frt models, 161
inducible models, 160
K-Ras^{LSLG12D}, 158–160
K-Ras^{LSLG12V}, 160
overview, 158
pharmacological studies, 163
prospects, 164–165
stroma targeting, 163–164
target validation, 161–163
overview, 117–118
therapeutic targeting
phosphatidylinositol 3-kinase, 124–125, 129
RAC1, 122–124
RAF, 125–129

- RAL, 124
 - rationale, 121–122
 - tumorigenesis, 118–121
 - pancreatic organoids
 - human studies, 175–176
 - mouse studies
 - coculture studies, 174–175
 - KRAS activation, 174
 - KRAS mutation, 172
 - signaling, 173
 - prospects, 176–177
 - PI3K signaling, 27, 32–34, 36, 38
 - plasma membrane interactions, 84
 - posttranslational modifications, 63–71
 - structure, 104–105
 - synthetic lethality in cancer
 - effector pathway targeting, 203–205
 - functional genetic screening, 208–212
 - oncogenic stress and adaptation, 205–208
 - overview, 202–203
 - prospects for study, 212–214
 - KSR, 21–22, 38, 245–246, 252
- L**
- LATS1, 17
 - LIMK2, 271–272
 - LRPPRC, 271
 - Lung cancer. *See* KRAS
- M**
- Macrophage, KRAS modulation in cancer, 186–187
 - MANGL, 97
 - MAPK. *See* Mitogen-activated protein kinase
 - MDS. *See* Myelodysplastic syndrome
 - MEK, inhibitor classes, 249–250
 - MEK1
 - BRAF complex, 17, 20
 - domain organization, 251
 - Mitogen-activated protein kinase (MAPK). *See also* Extracellular regulated kinase
 - domain organization, 251
 - KRAS
 - immune modulation, 181, 184–185, 190
 - signaling, 202
 - targeting in cancer, 203–204
 - nanocluster signaling, 87–88
 - oncogenic signaling, 245–246
 - Ras effector, 3, 30, 241–242
 - therapeutic targeting in cancer, 246–247
 - MRAS
 - cell differentiation role, 99–100
 - cell polarity role, 96–97
 - diseases, 97–99
 - phylogeny, 93–94
 - RAF activity regulation, 95–96
 - regulation, 94–96
 - mTORC1, 31
- mTORC2, 31
 - Myelodysplastic syndrome (MDS), 135, 138–140
- N**
- Nanocluster. *See* Plasma membrane, Ras interactions
 - NANOG, 100
 - Nerve growth factor (NGF), 9
 - Neurofibromin (NF1), 229, 258–259
 - functions, 266–267
 - neurofibromatosis type 1, 266
 - protein–protein interactions, 270–271
 - Sec14-PH module, 268–269
 - structure, 264–265, 267–271
 - NF- κ B. *See* Nuclear factor κ B
 - NF1, 135–136, 140–146
 - NF1. *See* Neurofibromin
 - NGF. *See* Nerve growth factor
 - Noonan syndrome (NS), MRAS mutation, 98–99
 - NOTCH, 64
 - NRAS
 - G domain structure comparison between isoforms, 107–110
 - hematological malignancies, 136–138
 - history of study, 1–2
 - PI3K signaling, 27, 32
 - posttranslational modifications, 64–66, 69, 71
 - NRF2, 207
 - NS. *See* Noonan syndrome
 - Nuclear factor κ B (NF- κ B), 179–180, 204
- O**
- OCT4, 100
 - Organoid
 - colon organoids, 176
 - culture, 171–172
 - pancreatic organoids
 - human studies, 175–176
 - mouse studies
 - coculture studies, 174–175
 - KRAS activation, 174
 - KRAS mutation, 172
 - signaling, 173
 - prospects, 176–177
- P**
- p120GAP/RASA1, 257–260, 262–263, 267
 - P97/VCP, 272
 - PAK1, therapeutic targeting in pancreatic cancer, 124
 - Pancreatic cancer. *See* KRAS
 - PAT. *See* Protein acyltransferase
 - PDE6 δ , 71, 223
 - PEGPH20, 164
 - Phosphatidylinositol 3-kinase (PI3K)
 - Ras
 - binding interface, 31–32
 - effector, 3

Index

R

- Ras signaling in cancer
 - migration and metastasis promotion, 35–36
 - overview, 33–34
 - therapeutic targeting, 36–38
 - tumor stroma, 34–35
- signaling
 - pathway, 30–31
 - Ras signaling in health, 32–33
 - therapeutic targeting in pancreatic cancer, 124–125, 129
- PI3K. *See* Phosphatidylinositol 3-kinase
- PIX, 97
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- Plasma membrane, Ras interactions
 - dimers, 82–84
 - KRAS inhibitor development, 222–223
 - nanocluster
 - molecular modeling, 98
 - signal processing, 87–88
 - sorting and lipid composition, 84–87
 - spatial organization on membrane, 80–84
 - targeting, 79–81
- PLEXIN-B1, 99
- Plexins, 259
- PLK1, 211
- PLX-8394, 249
- Posttranslational modifications, Ras
 - CAAX processing, 62–65
 - conditional modifications
 - acetylation, 69
 - nitrosylation, 69
 - phosphorylation, 67–68
 - ribosylation by bacteria, 69
 - sumoylation, 68–69
 - ubiquitination, 68–69
 - consequences, 69–72
 - palmitoylation, 65–67
- PP1, 19
- PP1, 95–96
- PP2A, 19, 21
- PP5, 21
- PPI, inhibitor development, 229
- PREX1, 212
- Protein acyltransferase (PAT), 65
- Protein kinase A (PKA), 17, 271
- Protein kinase C (PKC), 17, 263
- PTEN, 31, 34, 125, 138
- PTPN11, 213
- RABEX5, 68
- RAC1, therapeutic targeting in pancreatic cancer, 122–124
- Radil, 8
- RAF. *See also specific RAFs*
 - activation
 - dimerization and phosphorylation, 19–21
 - 14-3-3 displacement, 18–19
 - overview, 17–18
 - Ras binding, 18, 30
 - asymmetric allosteric activation, 243–245
 - autoinhibition, 14–16
 - B-Raf–MEK1 complex, 17
 - domain organization and structure, 243–244
 - 14-3-3 binding, 16–17
 - Hsp90 chaperone complex, 17
 - inhibitor classes, 247–249
 - MRAS regulation, 95–96
 - oncogenic signaling, 245–246
 - postsignaling inactivation, 21
 - Ras binding, 106
 - Ras effector, 241–243
 - therapeutic targeting in pancreatic cancer, 125–129
 - types, 13
- RAF1, 211–212
- RAL, 94, 124, 204
- RALGDS, 3, 38
- Rap
 - downstream targets of Rap1, 7–9
 - history of study, 4
 - Rap2, 9
 - regulation, 4–5
- Ras. *See also specific isoforms*
 - effectors, 3, 28–30, 61–62
 - inhibitor development. *See also* KRAS
 - antibodies, 234–235
 - effector targeting. *See specific effectors*
 - nucleic acid inhibitors, 236–237
 - overview, 62, 227–229
 - peptides
 - linear peptides, 229–230
 - macrocyclic peptides, 230, 232–234
 - mechanisms of action, 231
 - stapled peptides, 230
 - prospects, 237
 - protein inhibitors, 235–236
 - overview, 27–28
 - plasma membrane. *See* Plasma membrane, Ras interactions
 - posttranslational modifications. *See* Posttranslational modifications, Ras
 - Raf binding, 18
 - SOS interactions. *See* SOS
 - therapeutic targeting, 9–10, 36–38, 112–113
- RASA2, 259
- RASA3, 259
- RASA4, 262
- RASAL1, 259, 262, 265
- RASAL2, 259
- RASAL3, 259
- RasGRP1, 49
- Rasip1, 8
- RAS Synthetic Lethal Network (RSLN), 213
- RCE1, 63–64, 212, 223
- Reelin, 36
- RHOG, 97

RIN1, 68
RKIP, 17
RSLN. *See* RAS Synthetic Lethal Network

S

SCH772984, 250
SCRIB, 96–97
Sema4D, 99
Semaphorin, 265
SE, 271
SGEF, 97
SHOC2, 95–96, 212
siRNA. *See* Small interfering RNA
SIRT2, 69
Small interfering RNA (siRNA), Ras inhibition, 236
SmgGDS, 62
SOS
 activation, 48–51, 54–56
 Ras interactions
 active site nucleotide displacement by SOS, 50, 52
 bistability in RAS activation by SOS, 56
 evolutionary impact of SOS on Ras, 56–57
 SOS activation by Ras–GTP, 52
 SOS blocking of Ras–GTP at allosteric site, 52–54
 stapled peptide Ras inhibitors, 230
 structure, 48–50
Spred1, 263, 271–272
Stellate cell, 189–191
STK33, 211
Synthetic lethality. *See* KRAS

T

TBK1, 211–212
T cell, KRAS modulation in cancer
 $\delta\gamma$ T cell, 188–189
 Th17 cell, 188
TET2, 136
TGF- β . *See* Transforming growth factor β
TIAM1, therapeutic targeting in pancreatic cancer, 123
TNF- α . *See* Tumor necrosis factor α
TNIK, 9
Traf2, 9
Trametinib, 250
Transforming growth factor β (TGF- β), 35, 184–185
Tumor necrosis factor α (TNF- α), 94

U

UBXD8, 263
ULK1, 33
Unfolded protein response (UPR), 206
UPR. *See* Unfolded protein response

V

Vemurafenib, 248

X

XPO1, 206

Y

YAP1, 122, 208, 213